

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**GENERTEC UNIVERSAL MEDICAL GROUP COMPANY  
LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 2666)**

**COMPLETION OF THE ISSUANCE OF 2023 PERPETUAL MEDIUM-TERM  
NOTES (TRANCHE 1) IN THE PRC  
BY CHINA UNIVERSAL LEASING CO., LTD.,  
A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY**

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 22 December 2023 (the “**Announcement**”) in relation to the issuance of the 2023 perpetual medium-term notes (tranche 1) (the “**T1 Notes**”) of an aggregate principal amount of up to RMB250 million by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the “**Issuer**”), a wholly-owned subsidiary of the Company. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that the issuance of the T1 Notes in the PRC was completed on 27 December 2023 and the actual issuance amount of the T1 Notes is RMB250 million. The T1 Notes are with a basic term of two years (i.e. the first term) and with every two years afterwards constituting each extended period. The Issuer will, at the end of the agreed first term and each extended period, be entitled to an option to extend the term of the T1 Notes. The T1 Notes will have a fixed coupon rate during the first term. At the end of the first term and each extended period (the “**coupon rate reset date**”), the coupon rate is subject to reset. The coupon rate for the first term will be the aggregation of the initial benchmark interest rate and the initial interest rate spread (where the initial benchmark interest rate will be the arithmetic mean of Government Bond yield with 2 years maturity periods as shown in China Bond Government Bond Yield Curve that published on China Bond information website (中國債券信息網) (www.chinabond.com.cn) or other websites as recognized by China Central Depository & Clearing Co., Ltd. (中央國債登記結算有限責任公司) five business days prior to the date of book-building process (rounded to 0.01%); and the coupon rate for the subsequent extended period will be the aggregation of the benchmark interest rate for such term, the initial interest rate spread, and 300 basis points (where the benchmark interest rate for such term will be the arithmetic mean of Government Bond yield with 2 years maturity periods as shown in China Bond Government Bond Yield Curve that published on China Bond information website (中國債券信息網) (www.chinabond.com.cn) or other websites as recognized by China Central Depository & Clearing Co., Ltd. five business days prior to the coupon rate reset date (rounded to 0.01%). The issue price is RMB100 per note, which is equal to 100% of the principal value of the T1 Notes.

By order of the Board  
**Genertec Universal Medical Group Company  
Limited**  
通用環球醫療集團有限公司  
**Peng Jiahong**  
*Chairwoman of the Board*

Beijing, PRC, 27 December 2023

*As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.*